Anzeige
Mehr »
Donnerstag, 16.10.2025 - Börsentäglich über 12.000 News
Silber durchbricht 50 US-Dollar - Vizsla Royalties zählt zu den größten Gewinnern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VM0 | ISIN: US8902608392 | Ticker-Symbol: TPM0
Tradegate
15.10.25 | 20:06
16,800 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TONIX PHARMACEUTICALS HOLDING CORP Chart 1 Jahr
5-Tage-Chart
TONIX PHARMACEUTICALS HOLDING CORP 5-Tage-Chart
RealtimeGeldBriefZeit
16,60017,00015:11
16,60017,00015:04

Aktuelle News zur TONIX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTonix CEO präsentiert Forschung zu Antikörper TNX-1500 auf Transplantationskongress in Japan5
DiTonix CEO presents anti-CD154 antibody research at Japan transplant congress2
DiXFRA NEW INSTRUMENTS AVAILABLE ON 14.10.2025144The following instruments on XETRA do have their first trading 14.10.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.10.2025 Aktien 1 CA19260V1067 Coinbase Global Inc. 2...
► Artikel lesen
09.10.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 202522
07.10.Tonix to advance cyclobenzaprine into phase 2 for depression11
07.10.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report3
30.09.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access280Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya (cyclobenzaprine...
► Artikel lesen
29.09.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report3
TONIX PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.09.Tonix Pharmaceuticals To Begin Phase 2 Study Of TNX-2900 For Prader-Willi Syndrome In 20261
29.09.Tonix to begin phase 2 trial of PWS treatment with orphan status2
29.09.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026228Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900...
► Artikel lesen
18.09.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder229Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL...
► Artikel lesen
17.09.Tonix Pharmaceuticals gets global rights to Lyme disease treatment15
17.09.Tonix In-Licenses TNX-4800 For Seasonal Lyme Disease Prevention-
17.09.Tonix sichert sich Lizenz für monoklonalen Antikörper zur Prävention von Lyme-Borreliose9
17.09.Tonix licenses monoclonal antibody for Lyme disease prevention3
17.09.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)132Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase 2/3 study Approximately 70 million people...
► Artikel lesen
17.09.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report7
20.08.SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP41
18.08.Tonix drops 20% despite winning approval for fibromyalgia drug56
Weiter >>
89 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1